Advances in Management of Chronic Hepatitis D Infection

Compared with no treatment, bulevirtide was associated with normalization of liver enzymes and undetectable or reduced levels of hepatitis D RNA at 48 weeks.

Hepatitis D virus (HDV) depends on hepatitis B infection to replicate, and chronic hepatitis D infection is associated with excess risk for accelerated cirrhosis and liver cancer. Based on early testing in humans, bulevirtide (which blocks a hepatic polypeptide needed for viral entry) received conditional approval in the EU and Russia. In a phase 3 industry-sponsored clinical trial, investigators randomized 150 patients with hepatitis D (mean age, 42; 57% male; 47% with cirrhosis; 90% with undetectable hepatitis B e antigen) to receive daily subcutaneous bulevirtide (2 mg or 10 mg) or no treatment. Normalization of alanine aminotransferase (ALT) levels and reduction in HDV RNA to undetectable or by ≥2 log₁₀ IU/mL at 48 weeks (the primary en…

Reviewing Author

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Hana M. El Sahly, MD

Disclosures

Grant/Research SupportNational Institutes of Health

Advances in Management of Chronic Hepatitis D Infection

Topics

Reviewing Author